Transcatheter Aortic Valve Replacement (TAVR/TAVI, Percutaneous Replacement)


Article Author:
Hadi Mahmaljy


Article Editor:
Michael Young


Editors In Chief:
Lawrence Lee
Michael Firstenberg
Lawrence Greiten


Managing Editors:
Avais Raja
Orawan Chaigasame
Carrie Smith
Abdul Waheed
Khalid Alsayouri
Kyle Blair
Trevor Nezwek
Radia Jamil
Erin Hughes
Patrick Le
Anoosh Zafar Gondal
Saad Nazir
William Gossman
Hassam Zulfiqar
Navid Mahabadi
Hussain Sajjad
Steve Bhimji
Muhammad Hashmi
John Shell
Matthew Varacallo
Heba Mahdy
Ahmad Malik
Sarosh Vaqar
Mark Pellegrini
James Hughes
Beata Beatty
Daniyal Ameen
Altif Muneeb
Beenish Sohail
Nazia Sadiq
Hajira Basit
Phillip Hynes
Komal Shaheen
Sandeep Sekhon


Updated:
5/18/2019 5:41:04 PM

Introduction

Surgical aortic valve replacement has been the standard treatment for patients with severe symptomatic aortic stenosis (AS). Previously, patients determined to be at high risk for surgery could only be offered diuretics and balloon valvuloplasty which served as palliative treatment and had no effect on long-term outcomes. The development of transcatheter aortic valve replacement (TAVR) has emerged as a lifeline for patients considered to be inoperable providing both improvement in symptoms and statistically significant mortality benefit.[1][2][3]

The concept of transcatheter balloon expandable valves was first introduced in the 1980s by a Danish researcher by the name of H. R. Anderson who began testing this idea on pigs. In 2002, Dr. Alain Cribier performed the first successful percutaneous aortic valve replacement on an inoperable patient. The first approval of TAVR for the indication of severe AS in prohibitive risk patients came in 2011. In 2012, the FDA approved TAVR in patients at high surgical risk. In 2015 the indication was expanded to include “valve-in-valve” procedure for failed surgical bioprosthetic valves. Most recently, in 2016 the FDA approved the SAPIEN valve for use in patients with severe AS at intermediate risk.

Anatomy

The normal aortic valve is comprised of three leaflets attached to an aortic annulus normally opening to approximately 3 cm^2 to 5 cm^2. Echocardiography best evaluates the aortic valve. An aortic valve is considered severely stenotic when it opens to an area of less than or equal to 1.0 cm^2. High gradient AS is the most common form of severe AS as is defined by the mean gradient of greater than or equal to 40 mmHg and an aortic jet velocity of greater than 4 m/s across the valve. Low flow, low gradient severe AS is a less common form of severe AS. This subset of patients has low flow rate across the valve either due to systolic dysfunction with reduced ejection fraction or small ventricular volumes secondary to left ventricular hypertrophy (with normal LVEF). When LVEF is normal, low flow is defined as a stroke volume index =35 mL/m^2. Patients with low flow and depressed LVEF undergo dobutamine stress echocardiogram to differentiate true severe stenosis from "pseudostenosis."

Indications

Indications for aortic valve replacement (surgical or transcatheter) are as follows:

  1. Severe high-gradient AS with symptoms (class I recommendation, level B evidence)

  2. Asymptomatic patients with severe AS and LVEF < 50 (class I recommendation, level B evidence)

  3. Severe AS when undergoing other cardiac surgery (class I recommendation, level B evidence)

  4. Asymptomatic severe AS and low surgical risk (class IIa recommendation, level B evidence)

  5. Symptomatic with low-flow/low-gradient severe AS (class IIa recommendation, level B evidence)

  6. Moderate AS and undergoing other cardiac surgery (class IIa recommendation, level C evidence)

TAVR is approved for the following:

  1. Intermediate to prohibitive surgical risk patients with severe AS

  2. Valve-in-valve procedure for failed prior bioprosthetic valve

Contraindications

Life expectancy less than 12 months owing to a noncardiac cause, myocardial infarction within the last thirty days, congenital unicuspid, bicuspid or noncalcified valve, hypertrophic cardiomyopathy, need for emergency surgery, left ventricular ejection fraction less than 20%, severe pulmonary hypertension with right ventricular dysfunction, echocardiographic evidence of intracardiac mass, thrombus or vegetation, native aortic annulus smaller than 18 or larger than 25 mm, severe mitral regurgitation, MRI confirmed CVA or TIA within last six months, end-stage renal disease, mixed aortic valve disease (concomitant aortic regurgitation), or significant aortic disease.[4]

Preparation

A multidisciplinary heart team evaluates patients and puts them through extensive evaluation and pre-procedural testing to determine candidacy before undergoing a TAVR. The heart team consists of cardiothoracic surgeons, anesthesiologists, and cardiologists. In addition to transthoracic echocardiography, transesophageal echocardiography is often utilized for better visualization of aortic valve anatomy. Computed tomography angiography of the chest, abdomen, and pelvis are also performed for accurate measurement of the aortic annulus for determination of valve size. Additionally, this study is essential for visualization of anatomy and determination of the vascular procedure approach to be taken. Left heart catheterization is also done before TAVR to rule out any coexisting coronary artery disease that may be contributing to symptoms or may need revascularization before determination of either surgical or transcatheter approach. Factors that may influence the decision to pursue surgical aortic valve replacement include the need for concomitant coronary artery bypass grafting.

Technique

Multiple transcatheter aortic valves are available on the market. However, the only two currently FDA-approved for use in the United States are the SAPIEN valves (Edwards Lifesciences, Irvine, CA) and the CORE valves (Medtronic Fridley, MN). The SAPIEN valves are composed of bovine pericardial tissue and a chromium cobalt alloy frame. These valves are balloon expandable. The newest generation Medtronic valve is the EVOLUT-R. It is composed of porcine tissue and a nitinol frame. This valve has the advantage of being self-expandable (not requiring balloon expansion) and has the ability for repositioning after deployment. To date, there have not been any head-to-head trials comparing these two TAVR valves.[5][6][7]

The procedure is typically done in a hybrid room with both operating room and cath lab capabilities. The team consists of interventional cardiologist, cardiac surgeon, and anesthesiologist. The procedure is done under direct visualization with fluoroscopy and occasionally transesophageal echocardiogram (TEE) guidance. The most preferred and least invasive approach is the transfemoral approach. If not feasible, a more invasive method may need to be used.

Complications

Possible complications to TAVR include conduction disturbances and the need for a permanent pacemaker, stroke, paravalvular leak, vascular site complications, bleeding, annular rupture, left ventricular perforation, cardiac tamponade, need for surgery, acute myocardial infarction, acute kidney injury, infection, hypotension, and death.

A recent meta-analysis revealed statistically significant evidence of lower rates of both acute kidney injury and major bleeding, and a non-statistically significant trend favoring TAVR over SAVR on overall mortality and stroke. Additionally, there was a statistically significant reduction in length of stay. To the contrary, TAVR was associated with higher rates of vascular injury, paravalvular regurgitation and the need for permanent pacemaker placement. One caveat, being that high-risk patients in the TAVR cohort of the PARTNER 1-A trial had higher rates of stroke.[8][9][10]

Clinical Significance

Transcatheter aortic valve replacement is well established in the treatment of severe symptomatic aortic stenosis (AS) for patients considered to be at prohibitive risk for surgery. It is also an alternative to surgical correction in intermediate and high-risk patients.

Enhancing Healthcare Team Outcomes

For patients with severe aortic stenosis who are not candidates for open heart surgery, an alternative is transcatheter aortic valve replacement. The procedure is done by a multidisciplinary team that involves a cardiac surgeon, an interventional cardiologist, anesthesiologist and a radiologist. After the procedure, the patient needs monitoring in a cardiac ICU by critical care nurses. Such an approach may provide the best results with minimal morbidity. TAVR has now been done in thousands of patients in the US and Europe with a procedural success rate of 90%. The 30 day mortality rates have varied from 3-15%. At 2 years, some studies have shown mortality rates of about 35%. Early deaths are usually due to arrhythmias, heart failure and pulmonary complications. It should be emphasized that TAVR is only for patients deemed at high risk for an open procedure. [11][12][13](Level II)


Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Transcatheter Aortic Valve Replacement (TAVR/TAVI, Percutaneous Replacement) - Questions

Take a quiz of the questions on this article.

Take Quiz
A 67-year old male with aortic stenosis would like to undergo percutaneous transcatheter aortic valve replacement. He is otherwise healthy and feels that this is the right choice for him. What would you tell him about possible complications of this procedure?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
An 89-year-old man with a past medical history of coronary artery disease, atrial fibrillation, stroke, type II diabetes mellitus, hypertension, peripheral artery disease, chronic obstructive pulmonary disease and known symptomatic severe aortic stenosis is considering his options for treatment of his aortic stenosis. He is deemed extreme risk for surgery secondary to his extensive comorbidities and poor rehab potential. Which of the following therapeutic options has shown to have a mortality benefit in this patient population?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 78-year-old woman is evaluated for progressive dyspnea upon exertion. She has a prior history of aortic stenosis with placement of a surgical bioprosthetic valve ten years prior. An echocardiogram reveals a stenotic prosthetic valve with an estimated valve area of 0.8 cm2 and a mean gradient of 42 across the valve. Which of the following is true?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A patient is referred to valve clinic for consideration of transcatheter aortic valve replacement (TAVR) for symptomatic severe aortic stenosis. His medical history is significant for metastatic liver cancer, chronic obstructive pulmonary disease, and hypertension. In addition to severe aortic stenosis, his echocardiogram reveals mild aortic insufficiency and mildly elevates pulmonary pressures. Which of the following is a contraindication for undergoing TAVR?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A patient with severe aortic stenosis is considering surgical versus transcatheter aortic valve replacement. He is an intermediate risk for surgery. Which of the following is true?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up

Transcatheter Aortic Valve Replacement (TAVR/TAVI, Percutaneous Replacement) - References

References

Zoltowsk DM,Agrawal Y,Patel N,Sareen N,Kalavakunta JK,Gupta V,Halabi A, Association Between Pulmonary Hypertension and Transcatheter Aortic Valve Replacement: Analysis of A Nationwide Inpatient Sample Database. Reviews on recent clinical trials. 2018 Nov 19     [PubMed]
Iantorno M,Ben-Dor I,Rogers T,Gajanana D,Attaran S,Buchanan KD,Satler LF,Shults CC,Thourani VH,Waksman R, Emergent valve-in-valve transcatheter aortic valve replacement in patient with acute aortic regurgitation and cardiogenic shock with preoperative extracorporeal membrane oxygenator: A case report and review of the literature. Cardiovascular revascularization medicine : including molecular interventions. 2018 Nov 12     [PubMed]
Henn MC,Zajarias A,Quader N,Sintek M,Lasala JM,Koogler K,Damiano MS,Kachroo P,Miller DC,King CR,Melby SJ,Moon MR,Damiano RJ Jr,Maniar HS, Observed to expected 30-day mortality as a benchmark for transcatheter aortic valve replacement. The Journal of thoracic and cardiovascular surgery. 2018 Jul 27     [PubMed]
Wilson R,McNabney C,Weir-McCall JR,Sellers S,Blanke P,Leipsic JA, Transcatheter Aortic and Mitral Valve Replacements. Radiologic clinics of North America. 2019 Jan     [PubMed]
Edelman JJ,Thourani VH, Transcatheter aortic valve replacement and surgical aortic valve replacement: Both excellent therapies. The Journal of thoracic and cardiovascular surgery. 2018 Dec     [PubMed]
Gillam LD,Marcoff L, Echocardiographic Assessment of Transcatheter Aortic Valve Hemodynamics: More Tools for the Toolbox. JACC. Cardiovascular imaging. 2018 Nov 8     [PubMed]
Chetcuti SJ,Deeb GM,Popma JJ,Yakubov SJ,Grossman PM,Patel HJ,Casale A,Dauerman HL,Resar JR,Boulware MJ,Dries-Devlin JL,Li S,Oh JK,Reardon MJ, Self-Expanding Transcatheter Aortic Valve Replacement in Patients With Low-Gradient Aortic Stenosis. JACC. Cardiovascular imaging. 2018 Nov 8     [PubMed]
Coughlan JJ,Kiernan T,Mylotte D,Arnous S, Annular Rupture During Transcatheter Aortic Valve Implantation: Predictors, Management and Outcomes. Interventional cardiology (London, England). 2018 Sep     [PubMed]
Ando T,Adegbala O,Villablanca PA,Briasoulis A,Takagi H,Grines CL,Schreiber T,Nazif T,Kodali S,Afonso L, In-hospital outcomes of transcatheter versus surgical aortic valve replacement in non-teaching hospitals. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography     [PubMed]
Rodés-Cabau J,Sacco RL, Neurological Complications Following Aortic Valve Replacement: TAVR Better Than SAVR, But Room for Improvement. Journal of the American College of Cardiology. 2018 Oct 30     [PubMed]
Chen S,Redfors B,Ben-Yehuda O,Crowley A,Greason KL,Alu MC,Finn MT,Vahl TP,Nazif T,Thourani VH,Suri RM,Svensson L,Webb JG,Kodali SK,Leon MB, Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Prior Cardiac Surgery in the Randomized PARTNER 2A Trial. JACC. Cardiovascular interventions. 2018 Nov 12     [PubMed]
Spaziano M,Lefèvre T,Romano M,Eltchaninoff H,Leprince P,Motreff P,Iung B,Van Belle E,Koning R,Verhoye JP,Gilard M,Garot P,Hovasse T,Le Breton H,Chevalier B, Transcatheter Aortic Valve Replacement in the Catheterization Laboratory Versus Hybrid Operating Room: Insights From the FRANCE TAVI Registry. JACC. Cardiovascular interventions. 2018 Nov 12     [PubMed]
Egger F,Zweiker D,Freynhofer MK,Löffler V,Rohla M,Geppert A,Farhan S,Vogel B,Falkensammer J,Kastner J,Pichler P,Vock P,Lamm G,Luha O,Schmidt A,Scherr D,Hammerer M,Hoppe UC,Maurer E,Grund M,Lambert T,Tkalec W,Sturmberger T,Zeindlhofer E,Grabenwöger M,Huber K, Impact of On-Site Cardiac Surgery on Clinical Outcomes After Transfemoral Transcatheter Aortic Valve Replacement. JACC. Cardiovascular interventions. 2018 Nov 12     [PubMed]

Disclaimer

The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of Surgery-Cardiac. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for Surgery-Cardiac, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in Surgery-Cardiac, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of Surgery-Cardiac. When it is time for the Surgery-Cardiac board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study Surgery-Cardiac.